Man Group’s Corcept Therapeutics CORT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $3.13M | Sell |
77,604
-13,104
| -14% | -$490K | 0.01% | 1370 |
|
|
2025
Q4 | $3.16M | Sell |
90,708
-81,889
| -47% | -$6.43M | 0.01% | 1272 |
|
|
2025
Q3 | $14.3M | Sell |
172,597
-237,542
| -58% | -$17.2M | 0.02% | 633 |
|
|
2025
Q2 | $30.1M | Sell |
410,139
-219,036
| -35% | -$15.9M | 0.06% | 371 |
|
|
2025
Q1 | $71.9M | Buy |
629,175
+341,295
| +119% | +$20.8M | 0.18% | 117 |
|
|
2024
Q4 | $14.5M | Sell |
287,880
-62,653
| -18% | -$3.28M | 0.04% | 571 |
|
|
2024
Q3 | $16.2M | Sell |
350,533
-479,410
| -58% | -$17M | 0.04% | 524 |
|
|
2024
Q2 | $27M | Sell |
829,943
-668,977
| -45% | -$18.3M | 0.07% | 341 |
|
|
2024
Q1 | $37.8M | Buy |
1,498,920
+672,819
| +81% | +$15.9M | 0.1% | 239 |
|
|
2023
Q4 | $26.8M | Buy |
+826,101
| New | +$22.7M | 0.07% | 307 |
|
|
2023
Q3 | – | Sell |
-615,925
| Closed | -$17.8M | – | 447 |
|
|
2023
Q2 | $13.7M | Buy |
+615,925
| New | +$14.2M | 0.04% | 515 |
|
|
2023
Q1 | – | Sell |
-685,386
| Closed | -$15M | – | 442 |
|
|
2022
Q4 | $13.9M | Sell |
685,386
-63,015
| -8% | -$1.58M | 0.05% | 439 |
|
|
2022
Q3 | $19.2M | Buy |
+748,401
| New | +$20M | 0.09% | 266 |
|
|
2022
Q2 | – | Sell |
-445,740
| Closed | -$9.71M | – | 226 |
|
|
2022
Q1 | $10M | Sell |
445,740
-4,674
| -1% | -$99.4K | 0.03% | 607 |
|
|
2021
Q4 | $8.92M | Buy |
450,414
+42,549
| +10% | +$863K | 0.03% | 643 |
|
|
2021
Q3 | $8.03M | Buy |
407,865
+34,818
| +9% | +$729K | 0.03% | 659 |
|
|
2021
Q2 | $8.21M | Buy |
373,047
+84,292
| +29% | +$1.88M | 0.03% | 674 |
|
|
2021
Q1 | $6.87M | Sell |
288,755
-37,575
| -12% | -$1M | 0.03% | 568 |
|
|
2020
Q4 | $8.54M | Sell |
326,330
-449,798
| -58% | -$9.48M | 0.04% | 506 |
|
|
2020
Q3 | $13.5M | Buy |
776,128
+285,174
| +58% | +$4.54M | 0.05% | 382 |
|
|
2020
Q2 | $8.26M | Sell |
490,954
-260,753
| -35% | -$3.66M | 0.04% | 436 |
|
|
2020
Q1 | $8.94M | Buy |
751,707
+155,912
| +26% | +$1.93M | 0.06% | 326 |
|
|
2019
Q4 | $7.21M | Buy |
595,795
+375,033
| +170% | +$5.22M | 0.02% | 844 |
|
|
2019
Q3 | $3.12M | Buy |
220,762
+44,308
| +25% | +$544K | 0.01% | 1087 |
|
|
2019
Q2 | $1.97M | Sell |
176,454
-261,363
| -60% | -$2.91M | 0.01% | 1310 |
|
|
2019
Q1 | $5.14M | Buy |
437,817
+146,048
| +50% | +$1.81M | 0.02% | 911 |
|
|
2018
Q4 | $3.9M | Sell |
291,769
-178,623
| -38% | -$2.36M | 0.02% | 894 |
|
|
2018
Q3 | $6.59M | Buy |
470,392
+335,409
| +248% | +$4.69M | 0.02% | 842 |
|
|
2018
Q2 | $2.12M | Sell |
134,983
-54,650
| -29% | -$951K | 0.01% | 1342 |
|
|
2018
Q1 | $3.12M | Buy |
+189,633
| New | +$3.51M | 0.01% | 1092 |
|
Other funds holding CORT
ISL
VPM
VCM
PA
Man Group's CORT Position: Q1 2026 in Review
Man Group reduced its Corcept Therapeutics (CORT) stake by 14% in Q1 2026, selling an estimated $490K and leaving 77,604 shares worth $3.13M. The position accounts for 0.01% of the portfolio, ranked #1370.
Man Group first reported a position in CORT in Q1 2018 and has held it in 30 quarters since. The position peaked at $71.9M in Q1 2025. 351 funds tracked by Wall St. Rank hold CORT as of Q1 2026.
- Man Group held 77,604 shares of Corcept Therapeutics worth $3.13M as of Q1 2026.
- Man Group sold 13,104 Corcept Therapeutics shares in Q1 2026, an estimated $490K.
- Corcept Therapeutics made up 0.01% of Man Group's portfolio in Q1 2026, its #1370 holding.
- Man Group first reported a position in Corcept Therapeutics in Q1 2018 and has held it in 30 quarters since.
- Man Group's Corcept Therapeutics position peaked at $71.9M in Q1 2025.
- 351 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2026.
Based on Man Group's 13F filing for Q1 2026, filed 15 May 2026.